Immediate Impact
55 standout
Citing Papers
Inflammatory response of nanoparticles: Mechanisms, consequences, and strategies for mitigation
2024 Standout
Targeting ROS in cancer: rationale and strategies
2024 Standout
Works of C. O'Callaghan being referenced
LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
2020
Context-Dependent Roles for SIRT2 and SIRT3 in Tumor Development Upon Calorie Restriction or High Fat Diet
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| C. O'Callaghan | 48 | 97 | 104 | 138 | 12 | 335 | |
| Miao Yu | 26 | 36 | 91 | 191 | 11 | 300 | |
| Jay W. Yang | 27 | 30 | 115 | 206 | 9 | 325 | |
| Iain MacEwan | 38 | 45 | 110 | 123 | 15 | 345 | |
| Shruti Daga | 11 | 40 | 85 | 96 | 15 | 285 | |
| Fahmida Rasha | 52 | 80 | 24 | 115 | 15 | 318 | |
| Erika Fiorino | 21 | 76 | 35 | 135 | 15 | 321 | |
| Juan M. Adrian-Segarra | 11 | 58 | 49 | 152 | 10 | 314 | |
| Francesco Chiani | 18 | 30 | 101 | 161 | 13 | 304 | |
| Alexander Garcia | 84 | 39 | 26 | 154 | 12 | 331 | |
| Guoying Dong | 15 | 40 | 45 | 170 | 14 | 328 |
All Works
Login with ORCID to disown or claim papers
Loading papers...